Genotype Guided Versus Conventional Approach in Selection of Oral P2Y12 Receptor Blocker in Chinese Patients Suffering From Acute Coronary Syndrome

PHASE4CompletedINTERVENTIONAL
Enrollment

133

Participants

Timeline

Start Date

August 31, 2013

Primary Completion Date

August 31, 2015

Study Completion Date

August 31, 2015

Conditions
Acute Coronary Syndrome
Interventions
DRUG

Clopidogrel

"A platelet aggregation inhibitor. Also a P2Y12 Receptor Blocker of a drug class Thienopyridine.~Increasing evidence has shown that clopidogrel has wide inter-individual variability in pharmacokinetic and pharmacodynamic actions which lead to suboptimal antiplatelet effect especially in Asian population.~A standard loading dose of 300mg or 600mg(according to clinical protocol) will be given to patients."

DRUG

Ticagrelor

"A platelet aggregation inhibitor.~Though this agent has better anti-ischemic effects, it is associated with increased bleeding risk especially in Chinese patients whom are considered to be more prone to bleeding complications.~A loading dose of 180mg will be used."

Trial Locations (1)

Unknown

Department of Medicine, the University of Hong Kong, Queen Mary Hospital, Hospital Authority, Hong Kong

All Listed Sponsors
lead

The University of Hong Kong

OTHER

NCT01994941 - Genotype Guided Versus Conventional Approach in Selection of Oral P2Y12 Receptor Blocker in Chinese Patients Suffering From Acute Coronary Syndrome | Biotech Hunter | Biotech Hunter